Takeda Terminates Denali Partnership and Returns Dementia Asset Amid $1.26 Billion Strategic Restructuring

Takeda ends its neuro partnership with Denali Therapeutics and returns the DNL593 asset as part of a $1.26B restructuring involving 634 layoffs.

By: AXL Media

Published: Apr 7, 2026, 4:58 AM EDT

Source: Information for this report was sourced from Fierce Biotech

Strategic Realignments in the Neurodegenerative Pipeline

Takeda has officially terminated its longstanding neurological partnership with Denali Therapeutics, returning the investigational dementia therapy DNL593 to the California-based biotech. According to an April 3 filing with the Securities and Exchange Commission, the decision was driven by Takeda’s broader corporate restructuring efforts rather than any specific concerns regarding the safety or efficacy of the drug candidate. With this agreement dissolved, Denali now retains full ownership of the asset and has no remaining active collaborations with Takeda, ending a developmental journey that began in 2018.

Progress of the Independent Frontotemporal Dementia Program

Despite the withdrawal of its primary partner, Denali has expressed confidence in the continued development of DNL593, which is aimed at treating frontotemporal dementia-granulin (FTD-GRN). The therapy is currently being evaluated in a randomized, placebo-controlled Phase 1/2 clinical trial involving 85 participants. Early data released by Denali suggests the drug is capable of reaching the brain without triggering serious safety signals. The company anticipates reporting full results from this ongoing study by the end of 2026 as it seeks to address a condition for which there are currently no approved disease-modifying treatments.

Financial Overhaul and Large Scale Workforce Reductions

The dissolution of the partnership coincides with a significant reorganization at Takeda, intended to generate approximately $1.26 billion in cost savings by 2028. This fiscal strategy follows a 2024 plan aimed at pushing the company’s operating profit margin above 30%. As part of this transition, Takeda has announced the layoff of 634 employees associated with its Cambridge, Massachusetts, headquarters. These cuts include 247 positions based within Massachusetts and an additional 387 roles across other states, marking a period of contraction for the firm’s U.S. operations.